280 related articles for article (PubMed ID: 10476541)
1. Breast cancer highlights.
Kuter I
Oncologist; 1999; 4(4):299-308. PubMed ID: 10476541
[No Abstract] [Full Text] [Related]
2. Current controversies in breast cancer management.
Morrow M; Jordan VC; Takei H; Gradishar WJ; Pierce LJ
Curr Probl Surg; 1999 Mar; 36(3):163-216. PubMed ID: 10089889
[No Abstract] [Full Text] [Related]
3. Adjuvant treatment in node-negative, postmenopausal breast cancer.
Hutchins LF; Arick CL
Cancer Invest; 2001; 19(7):706-22. PubMed ID: 11577812
[No Abstract] [Full Text] [Related]
4. Tamoxifen versus raloxifene in the prevention of breast cancer.
Wickerham DL
Eur J Cancer; 2002 Nov; 38 Suppl 6():S20-1. PubMed ID: 12409060
[No Abstract] [Full Text] [Related]
5. Tamoxifen debate hinges on whose risk is high enough.
Reynolds T
J Natl Cancer Inst; 1998 Oct; 90(19):1428-30. PubMed ID: 9776407
[No Abstract] [Full Text] [Related]
6. STAR trial reports.
Eur J Cancer; 2006 Aug; 42(12):1694. PubMed ID: 16998956
[No Abstract] [Full Text] [Related]
7. [Effectiveness of adjuvant therapy for patients with early-stage (I-IIa) breast cancer].
Semiglazov VF
Vopr Onkol; 1998; 44(2):137-41. PubMed ID: 9615814
[No Abstract] [Full Text] [Related]
8. Breast cancer biology blossoms in the clinic.
Nass SJ; Hahm HA; Davidson NE
Nat Med; 1998 Jul; 4(7):761-2. PubMed ID: 9662357
[No Abstract] [Full Text] [Related]
9. Anti-estrogens come of age: a pioneer looks back.
Nelson NJ
J Natl Cancer Inst; 1998 May; 90(9):646-7. PubMed ID: 9586657
[No Abstract] [Full Text] [Related]
10. [Hormone therapy, chemotherapy and immunotherapy in breast carcinoma. The best strategy for your patient].
Sayer HG; Höffken K
MMW Fortschr Med; 2003 Jun; 145(24):40-2. PubMed ID: 12866298
[TBL] [Abstract][Full Text] [Related]
11. Estrogen receptor as a target for the prevention of breast cancer.
Jordan VC
J Lab Clin Med; 1999 May; 133(5):408-14. PubMed ID: 10235123
[No Abstract] [Full Text] [Related]
12. Raloxifene, retinoids, and lavender: "me too" tamoxifen alternatives under study.
Ziegler J
J Natl Cancer Inst; 1996 Aug; 88(16):1100-2. PubMed ID: 8757185
[No Abstract] [Full Text] [Related]
13. Tamoxifen vs the aromatase inhibitors: news from San Antonio, 2001.
Munster PN; Horton J
Cancer Control; 2001; 8(6):478-9. PubMed ID: 11807416
[No Abstract] [Full Text] [Related]
14. A prognostic table to guide practitioners advising patients on adjuvant systemic therapy in early breast cancer.
Stotter A
Eur J Surg Oncol; 1999 Aug; 25(4):341-3. PubMed ID: 10419700
[No Abstract] [Full Text] [Related]
15. [Adjuvant therapy in breast cancer].
Semiglazov VF
Vopr Onkol; 2000; 46(1):18-27. PubMed ID: 10789218
[No Abstract] [Full Text] [Related]
16. [The ATAC study on adjuvants in breast cancer. What kind of repercussions will it have on clinical practice?].
Gamucci T
Suppl Tumori; 2004; 3(4):S16. PubMed ID: 15206201
[No Abstract] [Full Text] [Related]
17. Re: Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999.
Du XL
J Natl Cancer Inst; 2003 May; 95(9):683; author reply 684-5. PubMed ID: 12734321
[No Abstract] [Full Text] [Related]
18. [Tamoxifen and breast cancer: is everything known already?].
Marchetti P; Porzio G; Trapasso T; Baldi PL; Ficorella C
Tumori; 1998; 84(6):A1-5. PubMed ID: 10080686
[No Abstract] [Full Text] [Related]
19. Upstaging tamoxifen? New classes of drugs emerging for breast cancer.
Twombly R
J Natl Cancer Inst; 2002 Apr; 94(7):474-5. PubMed ID: 11929942
[No Abstract] [Full Text] [Related]
20. Tamoxifen in early breast cancer.
Benson JR
Lancet; 1998 Aug; 352(9125):404-5. PubMed ID: 9717955
[No Abstract] [Full Text] [Related]
[Next] [New Search]
